title: [c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
abstract: OBJECTIVE
  It has been known that hepatocyte growth factor (HGF) induces gefitinib resistance in non-small cell lung cancer (NSCLC) cells. The possible mechanism may be related to the activation of the HGF receptor c-Met. The aim of this study is to investigate the involvement of c-Met and its downstream signaling pathway in the HGF-induced gefitinib resistance of NSCLC cells with different epidermal growth factor receptor (EGFR) gene types.
  
  
  METHODS
  NSCLC cell lines with different EGFR genes (PC-9, PC9/R, H292, and A549) were selected and induced by HGF. Cell survival was determined by MTT assay and the expression of Met and downstream signaling proteins were examined by Western blot.
  
  
  RESULTS
  Gefitinib inhibited the cell growth of PC9, H292, and A549 cell lines in a dose-dependent manner. The concentration-survival curve notably shifted to the right when induced by HGF. The apoptotic rate was lower when the cells were treated with HGF and gefitinib than when these cells were treated with gefitinib alone (P<0.05), particularly in PC9, H292, and A549 cells, but not in PC9/R. HGF stimulated the phosphorylation of Met and downstream signaling proteins in PC9, H292, PC9/R, and A549 cell lines. p-Met, p-Akt, p-Stat3, and p-Erk1/2 expressions were higher when the cells were treated with HGF and gefitinib than when these cells were treated with gefitinib alone, particularly in PC9, H292, and A549 cells, but not in PC9/R.
  
  
  CONCLUSIONS
  c-Met and its downstream signaling pathway possibly participated in the HGF-induced gefitinib resistance in NSCLC cells with different EGFR gene types.
authors.affiliation: Department of Respiratory Disease, Yanbian University Hospital, Yanji 133000, China.
authors.forename: Xianglan
authors.initials: X
authors.lastname: Xuan
authors.forename: Changshan
authors.initials: C
authors.lastname: An
authors.forename: Caicun
authors.initials: C
authors.lastname: Zhou
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D000077156:Gefitinib; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D006801:Humans; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D017228:Hepatocyte Growth Factor; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D000077156:Gefitinib
references.citation: Cancer Sci. 2007 Dec;98(12):1817-24
references.pmid: 17888036
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):177-84
references.pmid: 19208461
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: Oncogene. 2003 May 8;22(18):2812-22
references.pmid: 12743604
references.citation: Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):69-75
references.pmid: 12524227
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references.pmid: 18093943
references.citation: Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):1-6
references.pmid: 23327866
references.citation: Oncogene. 2009 Aug 27;28(34):3009-21
references.pmid: 19581933
references.citation: Clin Cancer Res. 2009 Nov 1;15(21):6630-8
references.pmid: 19843665